SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that four posters including data from three Phase 3 clinical trials of the company’s product candidate, doxepin for the treatment of insomnia, will be presented at the American Psychiatric Association (APA) 161st annual meeting in Washington, DC on Wednesday, May 7, 2008 from 12pm to 2pm ET. Data from these posters is embargoed until they are presented.
